MET and breast cancer: More specifically, a hypo-methylated L1PA2 transposon is found to act as an alternate promoter to the MET oncogene in breast cancer, chronic myeloid leukemia and colorectal cancer, and the L1PA2-MET expression is associated with enhanced malignancy and poor prognosis22–25.